Progressive Familial Intrahepatic Cholestasis Market

 Market Overview:

The 7 major progressive familial intrahepatic cholestasis markets are expected to exhibit a CAGR of 4.75% during 2025-2035.

The progressive familial intrahepatic cholestasis market has been comprehensively analyzed in IMARC's new report titled "Progressive Familial Intrahepatic Cholestasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Progressive familial intrahepatic cholestasis (PFIC) is a rare genetic disorder that affects the liver's ability to secrete bile, which can lead to progressive liver damage and, eventually, liver failure. There are three main types of PFIC, which are classified based on the specific genetic mutations that cause the condition: type 1, type 2, and type 3. Some of the common disease symptoms include persistent itching, yellowing of the skin and eyes (jaundice), poor weight gain or weight loss, and a swollen abdomen. Children with PFIC may also experience fatigue, weakness, and delayed growth and development. The diagnosis typically involves a combination of medical history, physical examination, and various laboratory tests. Initial testing includes blood investigations to evaluate liver function and imaging tests such as an ultrasound, MRI, or CT scan to examine the liver and bile ducts. If PFIC is suspected, a genetic test may be recommended to identify mutations in the genes known to cause PFIC. Additionally, a liver biopsy may be performed to assess the extent of liver damage and rule out other liver diseases.

The rising incidences of genetic mutations and the escalating demand for effective medications and therapies to treat such conditions are primarily driving the progressive familial intrahepatic cholestasis market. In addition to this, the increasing utilization of bile acid sequestrants, including cholestyramine and colestipol, to slow down the progression of the disease is creating a positive outlook for the market. Moreover, the rising usage of ursodeoxycholic acid (UDCA) to treat PFIC, as it can reduce bile acid levels and improve liver function, is further propelling the market growth. Besides this, several regulatory agencies across the globe are offering various incentives and assistance for developing novel treatments to combat rare diseases, such as PFIC. This, in turn, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of biliary diversion surgery for patients with PFIC type 1 or type 2 who do not respond to medical management is also bolstering the market growth. Apart from this, numerous key players are making extensive investments in research activities to investigate the use of gene therapy in order to address the underlying genetic mutations that cause the disease. This, in turn, is expected to drive the progressive familial intrahepatic cholestasis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the progressive familial intrahepatic cholestasis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for progressive familial intrahepatic cholestasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the progressive familial intrahepatic cholestasis market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the progressive familial intrahepatic cholestasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the progressive familial intrahepatic cholestasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current progressive familial intrahepatic cholestasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the progressive familial intrahepatic cholestasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the progressive familial intrahepatic cholestasis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the progressive familial intrahepatic cholestasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of progressive familial intrahepatic cholestasis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of progressive familial intrahepatic cholestasis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of progressive familial intrahepatic cholestasis by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of progressive familial intrahepatic cholestasis by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with progressive familial intrahepatic cholestasis across the seven major markets?
• What is the size of the progressive familial intrahepatic cholestasis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of progressive familial intrahepatic cholestasis?
• What will be the growth rate of patients across the seven major markets?
   

Progressive Familial Intrahepatic Cholestasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for progressive familial intrahepatic cholestasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the progressive familial intrahepatic cholestasis market?
• What are the key regulatory events related to the progressive familial intrahepatic cholestasis market?
• What is the structure of clinical trial landscape by status related to the progressive familial intrahepatic cholestasis market?
• What is the structure of clinical trial landscape by phase related to the progressive familial intrahepatic cholestasis market?
• What is the structure of clinical trial landscape by route of administration related to the progressive familial intrahepatic cholestasis market?